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ABSTRACT: In footprinting experiments, an increase in DNA cleavage with addition of ligand to a system 
may be due to a ligand-induced structural change. Ligand binding also enhances cleavage by displacing 
the cleavage agent from ligand-binding sites, thus increasing its concentration elsewhere. The theory and 
characteristics of this mass-action enhancement are given, and it is shown how it may be recognized. Results 
of DNase I footprinting of small oligomers, with actinomycin D as ligand, are analyzed to reveal which 
enhancements are due to mass action, and which can reasonably be ascribed to structural changes. Patterns 
in the footprinting plots from our experiments on actinomycin D binding to a 139-base-pair DNA fragment 
(with DNase I as a probe) are studied in the same way. The likely origins of these patterns are discussed, 
as are enhancements occurring with other probes commonly used in footprinting experiments. 
%e binding of drugs and other ligands may induce structural 
changes in DNA, which may be detected by a number of 
techniques. Since the rate of cleavage at a particular bond 
by agents such as DNase I depends on the local DNA structure 
(Lomonosoff et al., 1981; Drew, 1984; Suck et al., 1988), a 
natural way to study such changes is the footprinting tech- 
nique. In a footprinting experiment, one measures the amounts 
of DNA fragments of different lengths produced by a cleavage 
agent, and hence the amount of cutting taking place at various 
positions on a DNA oligomer, as a function of the ligand 
concentration (Dabrowiak & Goodisman, 1989; Dabrowiak 
et al., 1991). The amount of cutting at positions at or near 
ligand binding sites on DNA will decrease with ligand con- 
centration because the bound ligand prevents the approach of 
the cleavage agent (inhibition), but, at other positions, one 
might expect to see changes in cutting rate due to structural 
changes in the DNA. It should be noted that ligand-induced 
structural changes may lead to increases or decreases in the 
observed cutting rate. Thus, Low et al. (1984) observed large 
enhancements in cutting by DNase I and DNase I1 at many 
sites on a 160-base-pair DNA fragment when echinomycin 
was allowed to bind, in addition to inhibition of cutting near 
the drug binding sites (having the sequence CpG). These 
authors noted two possible explanations for the enhancements: 
structural changes in DNA and an attractive interaction be- 
tween the cleaving protein and the antibiotic, leading to in- 
creased concentration of the former near antibiotic-binding 
sites. They were able to dismiss the latter explanation. 
However, it is now clear (Ward et al., 1988; Dabrowiak & 
Goodisman, 1989; Dabrowiak et al., 1991; Portugal, 1989) that 
there is a third explanation for rate enhancements in DNase 
I footprinting experiments. Increased cutting at sites where 
no ligand binds can arise from a mass-action effect, caused 
by the bound ligand displacing the cleavage agent away from 
some regions of DNA, and thus increasing the concentration 
t We ackowledge the American Cancer Society, Grant NP-681, for 
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of cleavage agent elsewhere. This means that one may not 
automatically interpret cleavage rate enhancements as lig- 
and-induced structural changes, since the mass-action effect, 
due to the equilibrium between DNase I and DNA, is always 
present. Since mass-action and structural effects may exist 
simultaneously (Portugal, 1989; Ward et al., 1988), one must 
always consider whether observed enhancements can be ex- 
plained by mass action alone or if they are the result of a 
structural change as well. 
Below, we give a model for the mass-action enhancement 
and discuss how one can judge whether enhancements observed 
in a footprinting experiment have a structural origin. Then, 
we consider observed enhancements on small DNA oligomers 
and longer fragments, previously noted by other workers, which 
may be due to structural changes or mass-action effects. The 
experimentally observed intensity enhancements for actino- 
mycin D interacting with a 139-mer that we believe to be 
structural in origin are then presented and discussed. 
EXPERIMENTAL PROCEDURES 
The quantitative footprinting studies involving actinomycin 
D, the 139-base-pair HindIIIINciI restriction fragment of pBR 
322 DNA, and DNase I were as earlier described (Ward et 
al., 1988). The sequence of the restriction fragment and the 
location of strong and weak actinomycin D binding sites are 
shown in Figure 1. Autoradiographic spot intensities, cor- 
responding to relative amounts of 54 cleavage products of 
different lengths, were measured for 26 actinomycin D con- 
centrations ranging from 0 to 38.8 pM. 
The model used to interpret the resulting footprinting plots, 
plots of spot intensity as a function of total drug concentration, 
is described in detail elsewhere (Goodisman et al., 1992). The 
analysis takes into account binding of drug at the various 
binding sites, the mass-action enhancement, and binding of 
the drug to unlabeled carrier DNA (calf thymus). Correct 
description of the carrier, described as a concentration of strong 
binding sites and a concentration of weak binding sites, is 
important, since it is mainly the equilibria between drug and 
0 1992 American Chemical Society 
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FIGURE 1: Sequence of the 139-base-pair restriction fragment used 
for DNase I footprinting experiments, with actinomycin D as ligand. 
Filled rectangles show the location of strong actinomycin D binding 
sites while the unfilled reactangles indicate weak sites. 
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FIGURE 2: Footprinting plots for several sites on the 139-mer for low 
drug concentrations. Experimental intensities are shown as solid 
symbols; intensities calculated from a model including drug-binding 
and mass-action effects are shown as open symbols and broken lines. 
The pattern of interest is located at - 1.8 pM. 
carrier sites that determine the freedrug concentration present 
in the system. Parameters in the model, such as binding 
constants, were determined to minimize D, the mean-square 
deviation between experimental and calculated spot intensities. 
Although the value of D was of the same size as that of the 
apparent experimental error in the intensities, some systematic 
deviations between experimental and calculated footprinting 
plots were noted which may indicate structural changes. 
Figure 2 shows part of the footprinting plots (intensities for 
15 drug concentrations below 6.6 pM) for six cutting sites. 
Measured intensities are plotted as solid symbols; intensities 
calculated from the model with the best values of the param- 
eters are plotted as open symbols. In Figure 3, the full 
footprinting plots for eight other cutting sites are displayed 
with calculated intensities plotted as broken curves. We will 
be concerned later with two patterns: one at low drug con- 
FIGURE 3: (a) Footprinting plots for 54, 56, 58, and 143 on the 
139-mer. Sites 54,56, and 58 exhibit a sudden increase in intensity 
at -20 pM while site 143 exhibits a sudden decrease. (b) Footprinting 
plots for sites 59,92,96, and 145 on the 139-mer. Sites 59,92, and 
96 show sudden increases in intensity at -20 pM while site 145 shows 
a decrease. Theoretically calculated footprinting plots are shown as 
a broken line. 
centrations and one near the 20 pM drug concentration. 
The first is a slight (about 10%) decrease, followed by an 
increase, in intensity, with a minimum for a total drug con- 
centration of about 2 pM. It is seen most clearly on the 
footprinting plots for sites 52-56, 80-83, 89, and 90, which 
do not show drug binding, but the pattern seems also to be 
present, superposed on the intensity decrease due to drug 
binding, on the plots for these sites: 62-64,68,69,75-81, 83, 
87,92,114,120. The site number refers to the sequence shown 
in Figure 1. Scatter in the experimental intensity data for 
other sites makes it impossible to state whether this pattern 
is present there. By classifying all sites as positive, negative, 
or uncertain, we may summarize the situation by saying that 
sites from 54 to 103, in a well-resolved region of the autora- 
diogram, are either positive or uncertain and that sites from 
103 to 161, in a poorly resolved region, are either negative or 
uncertain. 
Another noticeable pattern occurs for total drug concen- 
tration between 16 and 24 pM. In this concentration range, 
the shapes of a number of footprinting plots change abruptly, 
with intensities showing a sharp increase or a sharp decrease 
with drug concentration. This results in a drop in the total 
cut of almost 25% at total drug concentration of about 20 pM. 
In general, binding-type plots show a decrease in intensity in 
this range and enhancement-type plots show an increase. Since 
footprinting plots for bonds blocked by drug binding to strong 
drug sites have very low intensities for a total drug concen- 
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tration of 16 pM, it is impossible to state whether they show 
this change in intensity, as is true for other low-intensity 
footprinting plots. Also, scatter in the experimental intensities 
may obscure the intensity changes we are looking for in some 
cases and give the impression of abrupt change when none is 
actually present in others. With these cautions, we find abrupt 
intensity increases in the following enhancement plots: 54, 
55, 56, 57, 58, 59, 90, 92, 94, 95, 96, 108, 126, 150. Weak- 
binding plots with abrupt intensity decreases are 71, 75, 76, 
77, 78, 79, 80, 83, 89, 99, 114, 120, 124, 143, 145, 154, and 
158. Plots for which intensities are high, but show no abrupt 
changes, are 85, 87, 98, 106, 112, 128, 147, 158, and 161. 
THEORY 
Mass-Action Enhancement. The cleavage rate, and hence 
the amount of cleavage, a t  any bond i of a DNA polymer is 
proportional to the local concentration of cleavage agent or 
probe, cpi,  and the probability that bond i is not blocked by 
bound ligand, vi. Thus 
Biochemistry, Vol. 31, No. 4, 1992 
(rate), = ki'cPivi (1) 
Structural effects change (rate)i by changing the rate constant 
ki'. The mass-action effect increases (rate)i by increasing cpi 
by a factor which is the same for all bonds i. Presence of 
ligand-induced structural changes in DNA could increase or 
decrease k; by different amounts for different bonds i .  
The amount of cleavage at any bond of a DNA oligomer 
is proportional to the local concentration of cleavage agent or 
probe, which is determined by equilibria between unbound or 
free probe and probe bound on DNA at the bond. If the 
binding constant for probe is much less than the binding 
constant for a ligand, binding of a ligand will always displace 
a bound probe molecule. If the ligand binds only at certain 
sites on DNA, and the probe can bind (and cut) at many sites, 
the effect of ligand binding is to reduce the number of sites 
available for probe binding. The competition between ligand 
and probe takes place on the carrier DNA, if it is present, as 
well as on the radiolabeled fragment. Since carriers are 
generally in much higher concentration than the radiolabeled 
fragment, it is the equilibrium with carrier DNA that deter- 
mines the free-drug and free-probe concentrations present in 
the system. 
Let c be the total concentration of probe-binding sites, on 
the carrier and on the fragment. For simplicity, we consider 
that all of these sites have the same equilibrium binding 
constant, K ,  where 
K = cp/(c - cp)(Pt - cp) (2) 
with cp the concentration of bound probe and pt the total probe 
concentration. The concentration of probe at any site is 
proportional to cp/c. The equilibrium equation (eq 2) is easily 
solved to give 
cP = I/ ,[P, + c + K-' - ((p, + c + K-')2 - 4 ~ p t ) ' / ~ ]  
If the ligand blocks a fraction (1 -A of the probe sites, the 
concentration of available sites is reduced to fc. The equi- 
librium is as in eq 2 except that fc is substituted for c and the 
concentration of bound probe in the presence of ligand is 
cpf = y2[Pt + fc + K-' - (bt + fc + K-')2 - .If~pt)'/'] 
The enhancement factor is the ratio of local concentrations, 
given by 
Goodisman and Dabrowiak 
(3) 
E increases as f decreases, as shown below, but it never be- 
comes infinite, even if all the probe sites are blocked. In fact 
lim E = 
f+ 
(4) 
Usually, not all probe sites can be blocked by ligand because 
of the sequence specificity of the latter. 
We now show that the slope dE/df is always negative. If 
we define a = pt + c + K-' and p2 = (pt + c + K-1)2 - 4cpt, 
then 
2CPt 
[Pt + K-'][Pt + c + K-' - ((p, + c + K')' - 4 ~ p , ) ' / ~ ]  
_ -   d E  
df  
This will be negative if 
' 1 2  
[pt + +]( [ + c + k l 2 - 4 7 )  > 
[ Pt + +] [ (Pt + ;) + c]  - 2cpt (5) 
To show this, note that pt/(pt + K-I) < 1, so that 
O > -  + 
pt + K-' 
-4c'pt 4c2pt2 
(pt + K-1)2 
and 
Therefore 
([; lJ 4 7 ) ' / 2  [ 1 1 1  ' P t + K  7 + c -  - + c + -  -- 
p t  + K-' 
which probes eq 5, so dE/df is always negative. Therefore, 
the enhancement E increases monotonically from 1 to E(0)  
(eq 4), asfgoes from 1 to 0, where 1 - f is the fraction of sites 
blocked by the drug. 
It is of interest to consider the behavior of E near f = 1, 
by examining the first few terms in the power series in 1 -f: 
E = 1 + cl(l -j) + cz(l -A2 + .... The first-order coefficient 
is 
r .I 
c + K-' - pt 
P 
Similarly, the second-order coefficient is 
c + K-' -pt c'(-2ptK-') I +  P3(a - 8) 
Higher coefficients all have a similar form, 1 plus terms in 
pt and K-'. If K-' is large compared to c and pt, these terms 
are negligible and E becomes 1 + (1 -A + (1 -Az +... or 
E = f l .  
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pM. This is close to what we found (Goodisman et al., 1992) 
by minimization of D, which confirms that the mass-action 
effect is mainly responsible for the enhancements observed. 
If the fraction of sites blocked by drug, 1 - f, is not large 
compared to unity, Le., for small ligand concentrations, the 
mass-action enhancement isf’ for all cutting sites. Whether 
this is in fact true can be ascertained by calculating the “initial 
relative slopes” of the footprinting plots for enhancement sites 
(Ward et al., 1988). This is done by fitting the intensities for 
the lowest ligand concentrations to a linear function of ligand 
concentration D,, given by 
Zj(Dt) = aj + bjDt (6) 
where j indexes the cleavage site. The initial relative slope 
is bj/aj and should be negative for sites showing inhibition due 
to ligand binding and positive for enhancement sites and for 
weak ligand-binding sites, if the ligand concentrations used 
for the initial relative slopes are not sufficiently high to give 
appreciable binding at such sites. Note that, to get the 
magnitude of K, from slopes, one requires a plot of Zj vs 
bound-drug concentration cb, and calculation of cb requires 
a knowledge of drug-binding constants. However, for small 
total drug concentration D,, the free-drug and bound-drug 
concentrations are linear in Dt. 
For enhancement sites, the initial relative slope should be 
Kecb/D,, since cb is linear in Dt. This means it should be the 
same for all sites. Initial relative slopes have been calculated 
for this experiment, with the standard deviations obtained from 
the scatter in the footprinting intensities (Ward et al., 1988). 
The slopes were statistically the same, except for sites im- 
mediately adjacent to drug-binding sites, for which they were 
much larger. This was ascribed to an attractive drug-probe 
interaction or a distortion of DNA. 
Other authors (Low et al., 1984, 1986) have plotted the 
quantity Fj = In [Zj(Dt)/Zj(0)] vs site number j ,  using the 
results of only two footprinting experiments, one in the 
presence of drug at concentration D, and one in the absence 
of drug. In these experiments, D, was large enough so that 
binding sites were essentially saturated with drug. Fj > 0 is 
an enhancement and Fj < 0 shows the effect of drug binding, 
allowing enhancement sites to be identified from a plot of Fj 
vs j .  A problem with this approach is that no estimate of the 
uncertainty of Fj is obtained, as one gets from relative initial 
slope plots, so it is not clear whether F/ is really different for 
different sites. Furthermore, without footprinting plots (Ij vs 
D, for several values of Dt), one cannot know whether all sites 
with Fj > 0 are enhancement sites or whether some are also 
affected by weak binding. The presence of weak ligand sites 
would cause certain Fj to be smaller than others (but still 
positive) and the fact that 4 depends on j would then not imply 
structural changes. The effect of weak binding is seen in the 
139-mer footprinting plots for sites 143 and 145, shown in 
Figure 3. Similarly, sites 54-58 all show increased cutting 
with added drug, but it is evident from data for drug con- 
centrations above 20 p M  that 54 and 55  are affected by a weak 
binding site, whereas the others may truly be enhancements. 
Of course, values of Fj significantly higher than what can be 
explained by mass action do imply that a structural change 
is present in addition to the mass-action enhancement. 
ANALYSIS 
Small Oligomers. For small oligomers with a single lig- 
and-binding site, the analysis of footprinting plots is greatly 
simplified (Rehfuss et al., 1990a) because a single ligand- 
binding equilibrium relates the free-drug and bound-drug 
concentrations to Dt: 
3.4 7
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FIGURE 4: Enhancement calculated from a model (see eqs 2-5) in 
which all probe-binding sites have the same equilibrium constant, K 
= 1.5 X lo6 M-’. The total site concentration is c = 2 pM and the 
total probe concentration is pt = 0.1 pM. Points show the enhancement 
factor E as a function of 1 -f, the fraction of the probe sites blocked 
by bound ligand. The dashed straight line is the function E = 1 + 
x where x is k(l  -A and k is the initial slope of E. The top curve 
is E = (1 - x)-’.  The middle curve is E = E&?. 
Characteristics of Mass-Action Enhancement. The points 
in Figure 4 show the enhancement E as a function off,  cal- 
culated according to eq 3, as well as various approximations 
to it (dashed lines). The parameters used for this example were 
pt = 1 X lo-’ M, c = 2 X lo4 M, K = 1.5 X lo6 M-l, giving 
a maximum enhancement E(0)  of 3.5. Calculating k as the 
initial slope of our enhancement factor, -dE/dfforf = 1, and 
puttingX = k(1 -A, we have plotted 1/(1 -X) vsf, obtaining 
the top curve in Figure 4. It is seen to fit the actual en- 
hancement well forfnear 1 but to increase too rapidly forf 
smaller than about 0.3; it cannot be correct for smallfsince 
it incorrectly becomes infinite when 1 -f = k-’. 
Functions which behave like 1/(1- X )  forfnear 1 but drop 
below it asfdecreases are the power series, Cy=02 with n finite. 
The simplest such function is the linear function 1 + X ( n  = 
l ) ,  plotted in Figure 4 as the bottom curve. It is seen that 1 + X is a much poorer approximation to the exact E than is 
1/(1 - X ) ,  as is in fact found in the actual calculations on 
actinomycin (Goodisman et al., 1992). However, one can get 
a good approximation to E by using a higher value of n. The 
middle curve in Figure 4, for n = 6, tracks the points well for 
the full range off. 
In our actinomycin calculation (Goodisman et al., 1992), 
we write the enhancement factor as E = (1 - Kecb)-l or as a 
finite power series, C;=o(&Cby’, where cb is the concentration 
of bound ligand and K, is the enhancement coefficient, whose 
value is chosen to minimize D. Note that all footprinting plots, 
for inhibition (binding) sites as well as for enhancement sites, 
include the effect of enhancement. In inhibitions, E is mul- 
tiplied by a decreasing function of ligand concentration which 
depends on the ligand binding constant, and so gives different 
plots for different sites. All the footprinting plots which do 
not show the effect of ligand binding, however, are simply 
multiples of E.  If all can be fit by the same function, within 
a multiplying constant, it is suggested that one is observing 
a mass-action enhancement. 
The value of K, may be estimated a priori. If c is the 
concentration of probe-binding sites, and if one bound ligand 
blocks n of these, 1 -fshould be wb/c, so K, should be n/c .  
For actinomycin, which blocks seven sites from DNA cleavage, 
K, = 7 X lo6 M-’ since the concentration of probe sites is 1 
1062 Biochemistry, Vol. 31, No. 4, 1992 Goodisman and Dabrowiak 
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Here, D, - cb  is the free-drug concentration and c is the total 
concentration of ligand-binding sites, which is also the con- 
centration of oligomers. Furthermore, K,  can be calculated 
directly. Suppose that there are s cutting sites on the oligomer 
and that a single bound ligand blocks m of these. Then 1 - 
f = mcb/sc and the enhancement factor is E = (1 - mcb/sc)-l 
= (1 - Kecb)-I, or K,  = m/sc.  Since the maximum concen- 
tration of bound ligand possible is c, the maximum enhance- 
ment is then somewhere between 1 + K,c = 1 + m/s  and (1 
- K,C)-’ = (1 - m/s)-’. It is likely closer to the latter, since 
E = (1 - Kecb)-l tends to overestimate the enhancement slightly 
and E = 1 + Kecb tends to underestimate it (Figure 4). 
For example, for DNase I footprinting experiments, acti- 
nomycin D is known to block seven sites from cleavage (m  = 
7), four from the size of actinomycin D on DNA, and three 
sites due to an amino acid “loop” on the enzyme (Suck et al., 
1988). For a DNA n-mer, there are n - 3 bonds at which 
cleavage can take place, since DNase I cannot cut at the last 
three or four bonds at the 3‘-ends of the duplex (Lomonosoff 
et al., 1981; Suck et al., 1988), so s = n - 3. Then, for a 
dodecamer (n = 12), the maximum enhancement is (1 - ’/J1 
= 4.5. For a 16-mer, one gets a maximum enhancement of 
(1 - 7/13)-1 = 2.2, and for a 20-mer (1 - 7 / 1 , ) - 1  = 1.70. 
Lane et al. (1987) performed footprinting experiments for 
the duplexes d[(AT),AGCT(AT),], with n = 2, 3, and 4, 
corresponding to the three cases of the preceding paragraph. 
The drug was actinomycin D, and the cleavage agent was 
DNase I. On the 12-mer, inhibited cleavage due to drug 
binding occurred at all observed sites but one, for which en- 
hanced cleavage was in evidence. NMR measurements showed 
that the drug binds near the GC and not at the ends of the 
duplex, where the enhancements occurred. For the 20-mer 
(n = 4), cleavage enhancements, smaller in size than those for 
the 12-mer, were reported at unblocked sites. Enhancements 
for the 16-mer were intermediate between those for the other 
duplexes. It was also noted that the ratio of the APT cleavage 
rate to the TpA cleavage rate increased with n. The carrier 
DNA, which determines the probe concentration, was the same 
in all the experiments. Therefore, the cleavage rate en- 
hancements in this case and in others (Huang et al., 1988) 
cannot be explained by the mass-action model. Note that when 
the probe concentration is large, the mass-action enhancement 
is small (if P, >> K-’ and Pt > c, eq 4 shows that E is always 
about 1). Thus, it is likely that the rate increases observed 
by Lane et al. (1987) are structural in origin. 
Multisite DNA. Portugal (1989) studied enhancement of 
DNase I cleavage by netropsin binding to the Tyr-T DNA 
fragment, attempting to separate out the effects of the three 
mechanisms: mass-action, structural changes, and ligand- 
probe interactions. Netropsin is a minor groove ligand which 
does not greatly distort DNA upon binding (Kopka et al., 
1985). It was reported that 70-71% of the variance of the 
measured cleavage enhancements could be explained by any 
of the three mechanisms. Combinations of any two, or of all 
three, likewise explained 70-71% of the variance. This sug- 
gests that a large fraction of the variance simply arises from 
fluctuations or experimental errors in the measured en- 
hancements. However, since only values of F, (logarithm of 
the ratio of cleavage at bond j in the presence of drug to 
cleavage in the absence of drug) are given, one has no measure 
of experimental error in these experiments. 
The reported values of F, are plotted against bond number. 
The average of the 28 F, values which are positive is 0.75, 
corresponding to a maximum enhancement of 2.1. Since there 
are 47 bonds in this fragment and three netropsin sites, each 
of which blocks about 8 bonds from cleavage, and assuming 
that the three end bonds cannot be cleaved by DNase I, the 
maximum enhancement according to the mass-actibn model 
is (1 - 24/u)-1 = 2.2. Thus, the average enhancement observed 
is consistent with mass action. 
Selected footprinting plots (intensity vs total drug concen- 
tration) for the actinomycin D-139-mer interaction are shown 
in Figures 2 and 3, together with the footprinting plots cal- 
culated according to our model. By seeking the values of the 
parameters which minimized the sum of the squared deviations 
between experimental intensities and those calculated from 
the model, we found values for binding constants and the 
enhancement constant K,. The value of K,, 7.1 X lo6 M-l, 
is consistent with the mass-action model, which predicts, as- 
suming each bound ligand blocks 7 sites and the concentration 
of cutting sites is M, a value of 7.0 X lo6 M-l. It does 
not appear that, with the drug concentrations used, one reaches 
the maximum enhancement, which would be about (1 - 
10s/139)-1 = 3.7, since there are about 139 bonds and 15 in- 
dependent binding sites. 
A plot of initial relative slope vs site number for true en- 
hancement sites makes it easy to recognize deviations from 
constancy, if any. These deviations, which may be positive 
or negative, may be ascribed to structural changes. For ac- 
tinomycin D and netropsin binding to the 139-mer, we sug- 
gested on this basis (Ward et al., 1988) that there were 
structural changes adjacent to binding sites. For both drugs, 
most of the positive slopes were the same size within the 
standard deviations, and the average level of enhancement 
could be explained by mass action. Unusually large slopes 
were observed for netropsin at sites 52, 53,64, and 68; binding 
sites are found at 46-50 (5’-AAATA-3‘) and at 56-62 (5’- 
AATTTAA-3’). For actinomycin, unusually large enhance- 
ments were noted for sites 58 and 73, and actinomycin-binding 
sites of sequence 5’-XGCX-3’ are found at 5‘-63-66-3‘ and 
5’-68-71-3’ (Figure 1). 
Obviously, the calculated plots for enhancement sites cannot 
fit the experimental intensity data in detail, but only on the 
average, because of the scatter in the experimental points. 
However, when regular patterns appear in the deviations, they 
may indicate real effects which our model cannot take into 
account, such as structural changes. In the case of actinomycin 
D, one such pattern occurs at very low total drug concentra- 
tions, and another occurs at a total drug concentration of about 
20 pM. 
Figure 2 shows experimental intensities for a number of sites 
for drug concentrations below 7 pM. The small decrease and 
increase at about 2 pM is evident on some of these. If this 
effect is actually due to a structural change induced by drug 
binding, we may ask which drug-binding events are involved. 
For small drug concentration, the equilibrium that determines 
the free-drug concentration Do in terms of the total drug 
concentration D, is 
where K, is the strong-site binding constant on the carrier and 
c is the concentration of these sites. Using the values deter- 
mined by minimization of D, K, = 1.8 X lo7 M-’ and c = 5 
pM, a total drug concentration D, of 2 pM corresponds to a 
free-drug concentration of 3.6 X lo-* M. For a site j on the 
fragment with binding constant K,, the probability p j  that a 
drug is bound is determined by the equilibrium 
Footprinting and DNA Structural Changes 
Kj = Pj/[Do(1 - ~ j ) l  (9) 
sopj = D&/(1 + D&). The two strongest binding sites on 
the polymer have the sequence 5’-TGCT-3’ and are found at 
positions 62-65 and 136-139. The determined binding con- 
stants were 3.5 and 6.4 pM-l, respectively (Goodisman et al., 
1992). Then, with Do = 3.6 X lo-* M and KJ = 6.4 X lo6 
M-’, PJ = 0.19; with KJ = 3.5 X lo6 M-l, pJ = 0.11. Other 
sites are hardly loading drugs at these concentrations. Further, 
the intensity pattern is evident on almost all footprinting plots 
from 52 to 103, and apparently it is not present near the 
strongest binding site. Thus, the structural change in DNA 
would have to start some 30 base pairs away from the drug 
and extend some 50 base pairs further. These factors suggest 
that this pattern should not be ascribed to a structural change. 
The other pattern, for 16-24 p M  drug, is a sharp intensity 
decrease for binding-type plots and a sharp increase for en- 
hancement-type plots. The effect is found all over the frag- 
ment. This suggests that an abrupt increase in drug binding 
is occurring at certain sites, producing an abrupt increase in 
the effective concentration of DNase I, and hence an increase 
in cutting, at unblocked sites. 
At a drug concentration of 20 pM, many sites have ap- 
preciable drug loading. Equation 8 is not adequate to calculate 
Do, because the weak sites on the carrier become important 
in determining the free-drug concentration. Our calculations 
(Goodisman et al., 1992) show that when Dt = 17.2,20.3,23.8 
pM, Do = 3.5, 5.4, and 8.0 pM, respectively. According to 
eq 9, if KJ = 2 X lo5 M-l, pJ = 0.41 at Do = 3.5 pM. Thus, 
all sites with binding constants greater than or equal to 2 X 
lo5 M-I have appreciable drug loading. Thirteen such sites 
were identified in our study, and there are probably three 
others outside the part of the fragment measured in our 
footprinting experiments. Since binding sites are distributed 
all over the fragment, except in the regions 45-60 and 85-100, 
it is not surprising that the abrupt intensity changes occur for 
essentially all cutting sites. 
This drug-induced structural change, if that is what is oc- 
curring, causes a decrease in cutting by enzyme near drug- 
binding sites and an increase at other positions. This suggests 
that it is associated with increased drug binding, which we 
referred to previously as positive cooperativity. In our previous 
work (Goodisman et al., 1992), we therefore modeled the effect 
as an increase in all binding constants with the amount of drug 
bound. This mechanism for such cooperative binding could 
well be a change in the structure of the DNA fragment, acting 
to increase drug binding rather than to increase cleavage. 
DISCUSSION 
The local structure of DNA affects the cutting efficiency 
of DNase I (Drew & Travers, 1984). Intercalating ligands 
would appear to be the most likely to produce structural 
changes in DNA which can affect cleavage rates by DNase 
I or other probes, but groove-binding ligands may also produce 
such changes (Portugal, 1989). Suck et al. (1988) suggest that 
the strength of binding, and hence the cutting rate, of DNase 
I at a site depends mainly on the local minor groove width, 
which is large in regions rich in GC and small in regions rich 
in AT. Both kinds of regions then have reduced cutting 
compared to random sequence DNA. Bending and torsional 
stiffness also have an effect on the cutting by DNase I (Hogan 
et al., 1989). 
Actinomycin D, though it dimerizes in solution, binds as 
a monomer, intercalating in DNA at a site that almost always 
contains a G (Krugh et al., 1977; Rill et al., 1989). The 
formation of the actinomycin-DNA complex is entropy-driven, 
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and stacking forces are more important than hydrogen bonding 
(Chiao & Krugh, 1977). It seems reasonable that the binding 
of actinomycin D alters the stfucture of the polymer. Net- 
ropsin should disturb polymer structure less on binding (Kopka 
et al., 1985), but it leads to cleavage enhancements similar 
to actinomycin D in a footprinting experiment (Ward et al., 
1988; Fox & Waring, 1984). Furthermore, the size of most 
of the enhancements’is consistent with the mass-action model. 
This suggests that, rather than interpreting cleavage en- 
hancements as evidence of structural change; one should first 
consider the mass-action model and then interpret what this 
model leaves unexplained as due to structural or other changes. 
In addition to mass-action and structural changes, an at- 
tractive interaction between bound ligand and cleavage agent 
is a possible cause of enhanced binding (Low et ai., 1984; 
Rehfuss et al., 1990b; Ward et al., 1988). The larger increase 
in DNase I cleavage at bonds near actinomycin D binding sites 
may be due to this effect. However, similar increases occur 
when the porphyrin Mn-T4 is used as a cleavage agent 
(Rehfuss et al., 1990b). Large enhancements in cleavage by 
this agent on the 139-mer were observed at sites 60 (near the 
Act-D binding site at 62-65) and 95 (near the two sites at 
100-105). In view of the dramatically different structures of 
Mn-T4 and DNase I, a ligand-cleavage agent interaction is 
probably not the correct explanation. 
We have considered two possible structural changes on the 
139-mer by comparing measured footprinting plots for a large 
number of sites with plots calculated from a model (Goodisman 
et al., 1992) in which values for binding constants and other 
parameters are chosen to give the best possible agreement with 
experiment. One effect, the large and rapid changes in cutting 
intensity for total drug concentrations between 16 and 24 pM 
(free-drug concentrations calculated to be 3.5-8.0 pM), is 
apparently delocalized over the entire fragment. For these 
drug concentrations, about 16 drug-binding sites, distributed 
over almost the entire length of the fragment, are appreciably 
loaded. Perhaps a major change in polymer structure occurs, 
leading tQ a large increase in drug binding at the binding sites 
and, by way of the mass-action effect, an increase in cutting 
at  sites not blocked by drug. 
The other possible structural change occurs for a total drug 
concentration near 2 pM (free-drug concentration calculated 
as 0.04 pM). Since the strongest sites are at 62-65 and 
136-139, and the intensity pattern seems to be present for all 
sites up to about 93 and absent for sites with higher numbers, 
it seems unlikely that this is actually a structural change. Its 
origin is unknown. 
For small okigomers, one normally has only a single lig- 
and-binding site and only a very few footprinting plots showing 
enhancements. With so few enhancement sites, one cannot 
use the constancy of the enhancements as evidence for the 
mass-action effect, although noticeable deviations from con- 
stancy do indicate that other effects are operating. However, 
it is easy to calculate what the mass-action enhancement should 
be, simply by counting the sites. Deviations from predicted 
mass-action enhancements, which may be positive or negative 
in sign, may be ascribed to structural changes indicated by 
drug binding. On longer fragments, negative deviations from 
constant mass-action enhancement may be due to the existence 
of weak binding sites. In this case, smaller increases in cutting 
rate with drug concentration should occur for groups of con- 
tiguous bonds, corresponding to the size of the drug’s inhibition 
region. 
Enhancements and Other Probes. In addition to DNase I, 
the aforementioned mass-action effects are applicable to other 
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footprinting probes such as Fe-MPE (Dervan, 1986; Da- 
browiak et al., 1989a), the porphyrin Mn-T4 (Dabrowiak et 
al., 1989b), and various metal complexes incorporating o- 
phenanthroline as a ligand (Kuwabara et al., 1986; Uchida 
et al., 1989). Since these probes must bind in order to cleave 
DNA, at low probe to DNA ratios their effective concentration 
at all non-ligand-binding sites increases when ligand is added 
to the system. The observed rate increases would be subject 
to the same analysis as for DNase I. 
The case for the alkylating agents dimethyl sulfate (DMS) 
and diethyl pyrocarbonate (DEPC), often used as probes in 
footprinting experiments (Ephrussi et al., 1985; Portugal et 
al., 1988; Jeppesen & Nielsen, 1988), is less certain. If these 
agents bind to DNA, they too will exhibit mass-action effects 
in the footprinting experiment. 
CONCLUSIONS 
In this report we show how to analyze DNase I footprinting 
data for protein- and drug-induced structural changes in DNA. 
Since the ligand and DNase I are in equilibrium with DNA, 
varying the concentration of ligand affects the amount of 
DNase I bound to DNA. This is because ligand binding to 
DNA blocks access of the enzyme to certain sites, thereby 
causing the effective concentration of the enzyme to increase 
at all non-ligand-binding sites. This mass-action effect, re- 
sulting in an increase in the cleavage rate, must occur with 
all probes which exist in an equilibrium with DNA. The 
enhancement of rate is appreciable when the probe concen- 
tration is small. 
A ligand-induced structural change in DNA can cause a 
change, positive or negative, in the cleavage rate constant near 
the ligand site. The mass-action effect leads to a positive 
change in the amount of cleavage, which should be equally 
strong all over the DNA. In order to identify structural 
changes, it is first necessary to account for the rate en- 
hancement due to mass action. Then one may note those sites 
having cleavage rates above or below the values expected for 
redistribution of the probe molecules on DNA. 
REFERENCES 
Chiao, Y.-C. C., & Krugh, T. R. (1977) Biochemistry 16, 
747-755. 
Dabrowiak, J. C., & Goodisman, J. (1989) in Chemistry and 
Physics of DNA-Ligand Interactions (Kallenbach, N. R., 
Ed.) pp 143-174, Adenine Press, Guilderland, NY. 
Dabrowiak, J. C., Kissinger, K., & Goodisman, J.  (1989a) 
Electrophoresis IO, 404-4 12. 
Dabrowiak, J. C., Goodisman, J., & Ward, B. (1989b) Bio- 
chemistry 28, 3314-3322. 
Biochemistry, Vol. 31, No. 4, 1992 
Registry No. Actinomycin D, 50-76-0. 
Goodisman and Dabrowiak 
Dabrowiak, J. C., Stankus, A., & Goodisman, J.  (1991) in 
Nucleic Acid Targeted Drug Design (Propst, C., & Perum, 
T., Eds.) Marcel Dekker, Inc., New York, NY (in press). 
Dervan, P. B. (1986) Science 232, 464-471. 
Drew, H. R. (1984) J .  Mol. Biol. 176, 535-557. 
Drew, H. R., & Travers, A. A. (1984) Cell 37, 491-502. 
Ephrussi, A,, Church, G. M., Tonegawa, S . ,  & Gilbert, W. 
Fox, K. R., & Waring, M. J.  (1984) Nucleic Acids Res. 12, 
Goodisman, J., Rehfuss, R., Ward, B., & Dabrowiak, J. C. 
(1992) Biochemistry (preceding paper in this issue). 
Hogan, M. E., Robertson, M. W., & Austin, R. H. (1989) 
Proc. Natl .  Acad. Sci. U.S.A.  86, 9273-9277. 
Huang, Y.-Q., Rehfuss, R. P., LaPlante, S .  R., Boudreau, E., 
Borer, P. N., & Lane, M. J. (1988) Nucleic Acids Res. 16, 
Jeppesen, C., & Nielsen, P. E. (1988) FEBS Lett. 231, 
Kopka, M. J., Yoon, C., Goodsell, D., Pujura, P., & Dickerson, 
R. E. (1985) Proc. Natl. Acad. Sci. U.S.A. 82, 1376-1380. 
Krugh, T. R., Mosberry, E. S . ,  & Chiao, Y.-C. C. (1977) 
Biochemistry 16, 740-747. 
Kuwabara, M., Yoon, C., Goyne, T., Thederahn, T., & Sig- 
man, D. S .  (1986) Biochemistry 25, 7401-7408. 
Lane, M. J., LaPlante, S . ,  Rehfuss, R. P., Borer, P. N., & 
Cantor, C. R. (1987) Nucleic Acids Res. 15, 839-852. 
Lomonosoff, G. P., Butler, P. J., & Klug, A. (1981) J .  Mol. 
Biol. 149, 745-760. 
Low, C. W. L., Drew, H. R., & Waring, M. J. (1984) Nucleic 
Acids Res. 12, 4865-4879. 
Low, C. W. L., Drew, H. R., & Waring, M. J. (1986) Nucleic 
Acids Res. 14, 6785-6801. 
Portugal, J .  (1989) FEBS Lett. 251, 8-12. 
Portugal, J., Fox, K. R., McLean, M. J., Richenberg, J. L., 
& Waring, M. J. (1988) Nucleic Acids Res. 16, 3655-3670. 
Rehfuss, R., Goodisman, J., & Dabrowiak, J. C. (1990a) 
Biochemistry 29, 777-78 1. 
Rehfuss, R., Goodisman, J., & Dabrowiak, J. C. (1990b) in 
Molecular Basis of Specificity in Nucleic Acid-Drug In- 
teractions (Jortner, J., & Pullman, B., Eds.) pp 157-166, 
Kluwer Academic Publ., Amsterdam. 
Rill, R. L., Marsch, G. A,, & Graves, D. E. (1989) J.  Biomol. 
Struct. Dyn. 7, 591-605. 
Suck, D., Lahm, A., & Oefner, C. (1988) Nature 382, 
Uchida, K., Pyle, A. M., Morii, T., & Barton, J .  K. (1989) 
Ward, B., Rehfuss, R., Goodisman, J., & Dabrowiak, J. C. 
(1985) Science 227, 134-140. 
9271-9285. 
11125-11139. 
172-1 76. 
465-468. 
Nucleic Acids Res. 24, 10259-10279. 
(1988) Nucleic Acids Res. 16, 1359-1369. 
